ReviewReviews on recent clinical trials2014
Lung cancer mutations and use of targeted agents in Hispanics.
Review in Reviews on recent clinical trials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles.Cancer research communications · 2025Article
- Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis.JCO global oncology · 2024Article
- Tumor Molecular Profiling in Hispanics: Moving Towards Precision Oncology and Health Equity.Journal of racial and ethnic health disparities · 2023Article
- Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles.Clinical lung cancer · 2022Article
- Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico.Cancers · 2020Article
- Use of biomarker testing in lung cancer among Puerto Rico and Florida Physicians: Results of a comparative study.Journal of clinical pathways : the foundation of value-based care · 2019Article
- An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines.Cancer research · 2019Review
- Lung cancer early detection and health disparities: the intersection of epigenetics and ethnicity.Journal of thoracic disease · 2018Review
- Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Article
- Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer.Cancer control : journal of the Moffitt Cancer Center · 2016Article
- Translating Hispanic Genomic Factors in Lung Cancer Into Clinical Practice: EGFR Testing for Improved Outcomes.Gene, cell and tissue · 2016Article
- Variability in Cancer Risk and Outcomes Within US Latinos by National Origin and Genetic Ancestry.Current epidemiology reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Hispanic/Latinos (H/L) are expected to grow to over 24% of the USA population by 2050 and lung cancer is the number one cause of cancer death among H/L men. Due to the information that is becoming available via genetic testing, lung cancer molecular profiling is allowing for increasing application of personalized lung cancer therapies. However, to benefit the most people, development of these therapies and genetic tests must include research on as many racial and ethnic groups as possible. The purpose of this review is to bring attention to the fact that the mutations driving lung cancer in H/Ls differ in frequency and nature relative to the non-Hispanic White (WNH) majority that dominate current databases and participate in clinical trials that test new therapies. Clinical trials using new agents targeting genetic alterations (driver mutations) in lung cancer have demonstrated significant improvements in patient outcomes (for example, gefitinib, erlotinib or crizotinib for lung adenocarcinomas harboring EGFR mutations or EML4-ALK fusions, respectively). The nature and frequencies of some lung cancer driver mutations have been shown to be considerably different among racial and ethnic groups. This is particularly true for H/Ls. For example, several reports suggest a dramatic shift in the mutation pattern from predominantly KRAS in a WNH population to predominantly EGFR in multiple H/L populations. However, these studies are limited, and the effects of racial and ethnic differences on the incidence of mutations in lung cancer remain incompletely understood. This review serves as a call to address this problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.